Rosella Silvestrini

List of Publications by Year
in descending order

67 papers	2,971 citations	186265 28 h-index	161849 54 g-index
68 all docs	68 docs citations	68 times ranked	1846 citing authors

#	Article	IF	Citations
1	The Bcl-2 Protein: a Prognostic Indicator Strongly Related to p53 Protein in Lymph Node-Negative Breast Cancer Patients. Journal of the National Cancer Institute, 1994, 86, 499-504.	6.3	423
2	p53 as an Independent Prognostic Marker in Lymph Node-Negative Breast Cancer Patients. Journal of the National Cancer Institute, 1993, 85, 965-970.	6.3	226
3	Cell kinetics as a prognostic marker in node-negative breast cancer. Cancer, 1985, 56, 1982-1987.	4.1	207
4	Cell proliferation and its relationship to clinical features and relapse in breast cancers. Cancer, 1981, 48, 974-979.	4.1	161
5	Prognostic implication of labeling index versus estrogen receptors and tumor size in node-negative breast cancer. Breast Cancer Research and Treatment, 1986, 7, 161-169.	2.5	138
6	Relationship between proliferative activity and estrogen receptors in breast cancer. Cancer, 1979, 44, 665-670.	4.1	126
7	Correlation of Cell Kinetic Findings With Morphology of Non-Hodgkin's Malignant Lymphomas 2. Journal of the National Cancer Institute, 1977, 58, 499-504.	6.3	93
8	Expression of p53, Glutathione S -Transferase-Â, and Bcl-2 Proteins and Benefit From Adjuvant Radiotherapy in Breast Cancer. Journal of the National Cancer Institute, 1997, 89, 639-645.	6.3	91
9	Laminin receptors, collagenase IV and prognosis in node-negative breast cancers. International Journal of Cancer, 1991, 48, 529-532.	5.1	90
10	Urine Cell-Free DNA integrity as a marker for early bladder cancer diagnosis: Preliminary data. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1744-1750.	1.6	69
11	Multiple Marker Detection in Peripheral Blood for NSCLC Diagnosis. PLoS ONE, 2013, 8, e57401.	2.5	64
12	Cell proliferation in 3,800 node-negative breast cancers: Concistency over time of biological and clinical information provided by3H-Thymidine labelling index. International Journal of Cancer, 1997, 74, 122-127.	5.1	61
13	c-kit and SCF Expression in Normal and Tumor Breast Tissue. Breast Cancer Research and Treatment, 2004, 83, 33-42.	2.5	61
14	Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: A prospective study. Breast Cancer Research and Treatment, 1997, 43, 7-14.	2.5	60
15	Kinetics of human mammary carcinomas and their correlation with the cancer and the host characteristics. Cancer, 1974, 34, 1252-1258.	4.1	58
16	DNA content and kinetic characteristics of non-Hodgkin's lymphoma: Determined by flow cytometry and autoradiography. Cytometry, 1981, 2, 185-188.	1.8	56
17	Mitotic catastrophe and apoptosis induced by docetaxel in hormoneâ€refractory prostate cancer cells. Journal of Cellular Physiology, 2008, 217, 494-501.	4.1	51
18	Biological markers as indicators of response to primary and adjuvant chemotherapy in breast cancer. International Journal of Cancer, 1999, 84, 580-586.	5.1	49

#	ARTICLE	IF	CITATIONS
19	Urine Cell-Free DNA Integrity as a Marker for Early Prostate Cancer Diagnosis: A Pilot Study. BioMed Research International, 2013, 2013, 1-5.	1.9	48
20	Prognostic Relevance of Mitotic Activity in Patients with Node-Negative Breast Cancer. Modern Pathology, 2003, 16, 1067-1075.	5.5	46
21	Changes in biological markers after primary chemotherapy for breast cancers. International Journal of Cancer, 1995, 61, 301-305.	5.1	44
22	Relationship among estrogen receptors, proliferative activity and menopausal status in breast cancer. Breast Cancer Research and Treatment, 1981, 1, 253-262.	2.5	43
23	Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells. International Journal of Cancer, 1992, 52, 813-817.	5.1	43
24	Labeling Index as a Prognostic Marker in Non-Hodgkin's Lymphomas<xref ref-type="fn" rid="fn2">2</xref>, <xref ref-type="fn" rid="fn3">3</xref>, <xref ref-type="fn" rid="fn4">4</xref>. Journal of the National Cancer Institute, 1981, , .	6.3	39
25	Short-term variation in labeling index as a predictor of radiotherapy response in human oral cavity carcinoma. International Journal of Radiation Oncology Biology Physics, 1984, 10, 965-970.	0.8	36
26	Quality control for evaluation of the S-phase fraction by flow cytometry: A multicentric study. Cytometry, 1994, 18, 11-16.	1.8	36
27	Role of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer. Cellular Oncology (Dordrecht), 2013, 36, 439-448.	4.4	36
28	The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol. , 1998, 82, 159-167.		34
29	Estimation of differential in vitro sensitivity of non-hodgkin lymphomas to anticancer drugs. European Journal of Cancer, 1981, 17, 217-226.	0.9	32
30	Biological markers as indicators of pathological response to primary chemotherapy in oral-cavity cancers. , 1998, 79, 619-623.		28
31	Cell kinetics as a prognostic tool in patients with metastatic malignant melanoma of the skin. Cancer, 1987, 60, 2797-2800.	4.1	26
32	Increased Levels of Free Circulating Dna in Patients with Idiopathic Pulmonary Fibrosis. International Journal of Biological Markers, 2010, 25, 229-235.	1.8	26
33	Cell Kinetics of Solid Tumors with Time and Its Clinical Implication. Tumori, 1989, 75, 367-372.	1.1	25
34	Changes in cell kinetics induced by primary chemotherapy in breast cancer. International Journal of Cancer, 1991, 47, 380-383.	5.1	25
35	Reliability of an in vitro short-term assay to predict the drug sensitivity of human breast cancer. Cancer, 1985, 56, 450-456.	4.1	24
36	Cell proliferation and outcome following doxorubicin plus CMF regimens in node-positive breast cancer. International Journal of Cancer, 2000, 87, 405-411.	5.1	23

#	Article	IF	Citations
37	Application of anin vitro antimetabolic assay to human germ cell testicular tumors for the preclinical evaluation of drug sensitivity. Cancer, 1986, 58, 1441-1447.	4.1	21
38	Cell kinetics and in Vitro chemosensitivity as a tool for improved management of patients. European Journal of Cancer & Clinical Oncology, 1985, 21, 371-378.	0.7	19
39	Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1–3 node-positive rapidly proliferating breast cancer. Breast Cancer Research and Treatment, 2011, 125, 775-784.	2.5	19
40	Benefit from anthracyclines in relation to biological profiles in early breast cancer. Breast Cancer Research and Treatment, 2014, 144, 307-318.	2.5	18
41	Lonidamine as a modulator of taxol activity in human ovarian cancer cells: effects on cell cycle and induction of apoptosis. , 1998, 78, 377-384.		14
42	Role of Androgen and Estrogen Receptors as Prognostic and Potential Predictive Markers of Ductal Carcinoma in Situ of the Breast. International Journal of Biological Markers, 2015, 30, 425-428.	1.8	14
43	Increased levels of free circulating DNA in patients with idiopathic pulmonary fibrosis. International Journal of Biological Markers, 2010, 25, 229-35.	1.8	14
44	Quantitative immunohistochemical determination of cathepsin-D and its relation with other variables. Breast Cancer Research and Treatment, 1993, 26, 7-13.	2.5	13
45	A Quantitative Test for Chemosensitivity of Short-term Cultures of Human Lymphomas. Tumori, 1977, 63, 237-247.	1.1	10
46	Could cell kinetics be a predictor of prognosis in non-small cell lung cancer?. Lung Cancer, 1991, 7, 165-170.	2.0	10
47	Phase III randomized multicenter study on the effects of adjuvant CMF in patients with node-negative, rapidly proliferating breast cancer: twelve-year results and retrospective subgroup analysis. Breast Cancer Research and Treatment, 2008, 108, 259-264.	2.5	10
48	Docetaxel–ST1481 sequence exerts a potent cytotoxic activity on hormone–resistant prostate cancer cells by reducing drug resistance–related gene expression. Prostate, 2010, 70, 219-227.	2.3	10
49	Modulation by lonidamine on the combined activity of cisplatin and epidoxorubicin in human breast cancer cells. Breast Cancer Research and Treatment, 1997, 42, 103-112.	2.5	9
50	Accuracy of urine telomerase activity to detect bladder cancer in symptomatic patients. International Journal of Biological Markers, 2009, 24, 253-257.	1.8	9
51	Cell proliferation markers in human solid tumors: Assessing their impact in clinical oncology. Methods in Cell Biology, 2001, 64, 359-384.	1.1	8
52	Cell kinetics in the study and treatment of head and neck cancer. Cancer Treatment and Research, 1984, , 229-248.	0.5	8
53	Biological characterisation of primary and metachronous lesions in breast cancer patients. European Journal of Cancer, 1992, 28, 2006-2010.	2.8	7
54	The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a *post hoc* analysis of the IBIS 3 trial. Therapeutic Advances in Medical Oncology, 2020, 12, 175883591988899.	3.2	7

#	Article	IF	Citations
55	Relation of in vitro Drug Activity to Clinical Response in a Prospective Trial for Advanced Germ Cell Testicular Tumors. European Urology, 1989, 16, 450-455.	1.9	6
56	Biofunctional characteristics of in situ and invasive breast carcinoma. Cellular Oncology (Dordrecht), 2013, 36, 303-310.	4.4	6
57	In Vitro Activity of Alkylating Agents on Human Tumors as Measured by a Short-term Antimetabolic Assay. Tumori, 1985, 71, 555-561.	1.1	5
58	Absolute and relative activities of platinum-complexes on human tumors as evaluated by an antimetabolic in vitro assay. Investigational New Drugs, 1987, 5, 245-50.	2.6	5
59	Biological markers in hepatocellular carcinoma: Potential clinical implications. Journal of Surgical Oncology, 1993, 53, 18-20.	1.7	5
60	P53 Accumulation in Primary Breast Cancer: A Comparison between Immunohistochemistry and a Novel Luminometric Immunoassay. Tumor Biology, 1998, 19, 12-18.	1.8	5
61	Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models. Journal of Cellular and Molecular Medicine, 2011, 15, 316-326.	3.6	5
62	Comparison of an antimetabolic assay and an antiproliferative assay, both using 3h-thymidine incorporation, to test drug sensitivity of human tumors. International Journal of Cell Cloning, 1988, 6, 392-403.	1.6	4
63	Fixation Time and Microwave Oven Irradiation Affect Immunocytochemical p53 Detection in Formalin-Fixed Paraffin Sections. Applied Immunohistochemistry & Molecular Morphology, 1998, 6, 140-144.	2.0	4
64	In Vivo and in Vitro Proliferation Kinetics of Sarcoma 180 in Solid Form. Tumori, 1972, 58, 335-339.	1.1	3
65	Drug Sensitivity of Different Tumor Lesions from the Same Patient Evaluated by a Short-Term Assay. Tumori, 1988, 74, 137-144.	1.1	3
66	Biological Markers for Designing Clinical Protocols. Annals of the New York Academy of Sciences, 1993, 698, 271-278.	3.8	2
67	Cell Proliferation of the Primary Tumor Predicts Ipsilateral Axillary Node Disease in Elderly Breast Cancer Patients. International Journal of Biological Markers, 2013, 28, 24-31.	1.8	0